Anti–CTLA-4 therapy broadens the melanoma-reactive CD8 + T cell response-Reference-Cited by-同舟云学术

Anti–CTLA-4 therapy broadens the melanoma-reactive CD8 + T cell response

Published:2014-09-17 Issue:254 Volume:6 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Kvistborg Pia¹,Philips Daisy¹,Kelderman Sander¹,Hageman Lois¹,Ottensmeier Christian²,Joseph-Pietras Deborah²,Welters Marij J. P.³,van der Burg Sjoerd³,Kapiteijn Ellen³,Michielin Olivier⁴,Romano Emanuela⁴,Linnemann Carsten¹,Speiser Daniel⁴,Blank Christian¹,Haanen John B.¹,Schumacher Ton N.¹

Affiliation:

1. The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, Netherlands.

2. National Institute for Health Research Southampton Experimental Cancer Medicine Centre and Southampton University Hospitals, Tremona Road, Southampton, Hampshire SO16 6YD, UK.

3. Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, Netherlands.

4. Ludwig Center for Cancer Research, Department of Oncology, University of Lausanne, Rue Pierre-Decker 4, 1011 Lausanne, Switzerland.

Abstract

Anti–CTLA-4 treatment increases the diversity of the melanoma-specific CD8 T cell response.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference34 articles.

1. Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients

2. CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma

3. Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer